Phase I Trial of DOC1021 Cell-Based Immunotherapy for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma

About
Share
Copy link
Copying text was successful.
442
Presenter: William Decker Professor, Baylor College of Medicine Houston, TX, USA
Release Date: November 27, 2025
Congress: SITC 2025
Area: Oncology
Description:

Professor William Decker discusses the Phase I Trial of DOC1021 cell-based immunotherapy for resectable or borderline resectable pancreatic ductal adenocarcinoma at SITC's 40th Anniversary Annual Meeting.